News
News
Upcoming Events
Subscribe
Our Company
Our Story
Our Vision
CEO Statement
Board of Directors
Alzinova Team
Advisers & Collaborators
Patients & Families
Alzheimer's Patients
Impact on Society
The Unmet Medical Need
R & D
Alzheimer's Disease
Our Programs
Specific Targeting of Toxic Aβ Oligomers
The AβCC Peptide™ Technology
Investors
Overview
Press Releases
English
Swedish
Subscribe
Presentations
Company Presesentation
The Share
Share Information
Largest Shareholders
Share Capital Development
Rights Issues / Företrädesemissioner
Previous Share Issuances
Analyst Coverage
Financial Reports
English
Swedish
Financial Calendar
Corporate governance
General Meetings
Nomination Committee / Valberedning
Articles of Association
Auditor
Board of Directors
Management
Certified Adviser
IR Contact
Career
Contact
News
News
Upcoming Events
Subscribe
Our Company
Our Story
Our Vision
CEO Statement
Board of Directors
Alzinova Team
Advisers & Collaborators
Patients & Families
Alzheimer's Patients
Impact on Society
The Unmet Medical Need
R & D
Alzheimer's Disease
Our Programs
Specific Targeting of Toxic Aβ Oligomers
The AβCC Peptide™ Technology
Investors
Overview
Press Releases
English
Swedish
Subscribe
Presentations
Company Presesentation
The Share
Share Information
Largest Shareholders
Share Capital Development
Rights Issues / Företrädesemissioner
Previous Share Issuances
Analyst Coverage
Financial Reports
English
Swedish
Financial Calendar
Corporate governance
General Meetings
Nomination Committee / Valberedning
Articles of Association
Auditor
Board of Directors
Management
Certified Adviser
IR Contact
Career
Contact
Home
/
Investors
/
Rights Issue 2022
Rights issue / Företrädesemission 2022
Rights Issue 2022
